SEC Contract Filing

Filing Date: 2022-11-10

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-amendmentno1tol.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic071f2b8a16b4d738edd7a08f95b2734_1"></div><div style="min-height:61.92pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">EXECUTION VERSION</font></div></div><div style="margin-top:9.55pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</font></div><div style="margin-top:9.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), entered into as of September 26, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), is entered into by and between LianBio Inflammatory Limited, a company limited by shares organized and existing under the laws of Hong Kong Special Administrative Region of the People&#8217;s Republic of China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lian</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and Lyra Therapeutics, Inc., a Delaware corporation, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lyra</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Lian and Lyra are each referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:206.47pt;padding-right:206.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INTRODUCTION</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Lian and Lyra entered into a License and Collaboration Agreement, dated May 31, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for the Development, Manufacture, and Commercialization of Compounds and Licensed Products in the Field in the Territory&#59; and</font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font><br></font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Parties wish to amend the Agreement to further clarify certain of Lian&#8217;s and Lyra&#8217;s Development and milestone payment commitments under the Agreement, as provided herein.</font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font><br></font></div><div style="padding-left:7.1pt;padding-right:6.85pt;text-align:justify;text-indent:28.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in cons